Search Videos and More
Podcast
Season 1, Episode 6: Dana-Farber in the Time of COVID
A beauty… that in some cases becomes tragic. It's not the way most people would describe a virus. In the simplest of terms, a virus is a snippet of genetic code. It can't reproduce on its own. In order to replicate, it needs to infect and hijack a living cell.
News
Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes
Although stem cell transplantation is the only current therapy with the potential to cure myelodysplastic syndromes (MDS), it is rarely used as an initial treatment for older patients because it hasn’t been proven superior to other therapies. New research by Dana-Farber Cancer Institute investigators stands to overturn that practice.
News
In Memoriam: David Morse Livingston, MD, Renowned Scientist and Esteemed Mentor
Dana-Farber mourns the loss of David Morse Livingston, MD, renowned scientist and esteemed mentor who not only made key discoveries, but also forged novel collaborations that opened new paths in cancer science.
News
New Study Finds Link Between Patient Survival and Changes in Tumor Cell Mass in Brain Cancer
Researchers at Dana-Farber Cancer Institute and MIT have developed a new way to determine whether individual patients will respond to a specific cancer drug or not.
Document
Mantle Cell Lymphoma Clinical Trial
Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.
News
Faculty Updates
Faculty Updates
Video
Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)
Dr. Marlise Luskin, a specialist in the Adult Leukemia Program at Dana-Farber Cancer Institute, explains an innovative trial that combines the BCL2 inhibitor, venetoclax with chemotherapy for older patients with ALL.
Podcast
Season 1, Episode 5: Turning Science Fiction into Fact
It's always fun to think about the future. Flying cars. Cities in the clouds. Colonies on Venus and Mars. OK, we didn't end up living like the Jetsons.
News
Genetic Signature of Tumor Cells Predicts Response to Chemotherapy Drug for Patients with Form of Ovarian Cancer
For more than two decades, the chemotherapy drug gemcitabine has been a mainstay treatment for several types of cancer, producing remissions in many patients on its own or conjunction with other drugs. Now, scientists at Dana-Farber Cancer Institute have uncovered, for the first time, genetic evidence of which patients with high-grade serous ovarian cancer (HGSOC) are likely to benefit from the drug.
Video
Stem Cell Transplant Beneficial for Older Patients with Myelodysplastic Syndrome
New research shows stem cell transplant represents the best therapeutic approach for older individuals with myelodysplastic syndrome. Dana-Farber Cancer Institute's Corey Cutler, MD, MPH, FRCPC explains more.
News
Highlights in Lung Cancer From ESMO 2021 - Pasi Jänne, MD, PhD, Discusses Promising Studies from the Meeting
In this exclusive MedPage Today video, ESMO Scientific Co-Chair Pasi A. Jänne, MD, PhD, director of the Chen-Huang Center for EGFR-Mutant Lung Cancer at Dana-Farber Cancer Institute in Boston, highlights some of the important lung cancer abstracts from the conference.
Video
Treatment for Adults with Acute Lymphoblastic Leukemia
Marlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute describes treatment for adults with acute lymphoblastic leukemia (ALL). She explains treatment considerations for younger adults and older adults with ALL.